KPRX KPRX
Company Profile ↓Company Overview
KPRX (KPRX) is a publicly traded company listed on . The valuation, growth and price-trend signals below summarize what matters most to investors and traders evaluating the stock.
Why Investors Should Care
Carries low leverage with a debt-to-equity ratio of 0.03.
Recent Developments
- Trailing 12 Months Year-on-year growth — revenue -100.0%, earnings -401.4%.
Growth & Price Performance
Compounded Sales Growth
| 5 Years: | - |
| 1 Year: | -100.00% |
Compounded Profit Growth
| 5 Years: | - |
| 1 Year: | -401.42% |
Stock Price Performance
| 1 Year: | +0.00% |
| 6 Months: | +12.39% |
| 3 Months: | +1.20% |
| 1 Month: | -0.39% |
Highlights auto-generated from reported financials and price data; not investment advice. Verify with official filings before acting.
- Price vs 50-DMABelow
- Price vs 200-DMAAbove
- RSI (14)49.11 · Neutral
Auto-generated from price history and fundamentals; not investment advice.
Price Chart
Technical Trend
Computed from daily close history using EMA cross, slope, and RSI signals.
Note: intraday data is not stored locally. “Hourly” uses the most recent 10 daily candles as a short-term proxy.
Fundamental Growth Charts
No fundamental data available for this stock.
Interactive charts for Revenue, Net Income, EBITDA, Free Cash Flow, EPS, ROE, ROCE, Gross/Net/Operating Margin and more — switch metric and period using the dropdowns above. CAGR is computed across the displayed window (quarterly CAGR is annualised). Visual growth charts make it easy to spot multi-year compounding trends at a glance — far faster than reading raw numbers in a table.
PROS
- In a confirmed uptrend (50-DMA above 200-DMA).
CONS
No notable concerns flagged.
* The pros and cons are auto-generated from financial metrics.
Valuation
Growth (CAGR)
Profitability & Returns
Balance Sheet & Liquidity
Ownership
Financial Snapshot
Financial Statements Quarterly Results · Profit & Loss · Balance Sheet · Cash Flows · Ratios
Quarterly Results
Figures in USD.
| Metric | Mar 2014 | Jun 2014 | Sep 2014 | Mar 2015 | Jun 2015 | Sep 2015 | Mar 2016 | Jun 2016 | Sep 2016 | Mar 2017 | Jun 2017 | Sep 2017 | Mar 2018 | Jun 2018 | Sep 2018 | Mar 2019 | Jun 2019 | Sep 2019 | Mar 2020 | Jun 2020 | Sep 2020 | Mar 2021 | Jun 2021 | Sep 2021 | Mar 2022 | Jun 2022 | Sep 2022 | Mar 2023 | Jun 2023 | Sep 2023 | Mar 2024 | Jun 2024 | Sep 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Mar 2026 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | - | - | - | - | - | - | - | - | - | - | - | - | - | - | 314.50K | 2.69M | 0 | 0 | 0 | 0 | 0 | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
| Operating Income | - | - | - | - | - | - | - | -3.83M | -3.38M | -2.92M | -3.33M | -4.14M | -2.38M | -2.80M | -3.18M | 828.64K | -1.87M | -3.45M | -1.97M | -1.72M | -2.01M | -2.01M | -2.82M | -3.04M | -3.57M | -2.40M | -3.70M | -1.92M | -2.63M | -5.92M | 13.22M | -2.54M | -3.60M | -2.33M | -2.40M | -794.44K | -2.51M |
| Net Income | - | - | - | - | - | - | - | - | - | -2.92M | -3.33M | -4.14M | -2.38M | -2.78M | -3.12M | 870.81K | -1.84M | -3.43M | -1.95M | -1.72M | -2.01M | -2.01M | -2.54M | -3.03M | -3.57M | -2.40M | -5.12M | -1.87M | -2.61M | -5.76M | 13.45M | -2.22M | -3.41M | -2.19M | -2.15M | 26.81K | -2.42M |
| Diluted EPS | - | - | - | - | - | - | - | - | - | - | - | - | -0.14 | - | - | 0.19 | - | - | -0.43 | - | -0.44 | -0.27 | -0.34 | -11.34 | -11.27 | -0.18 | -6.03 | -1.00 | -7.15 | -7.30 | 3.46 | -0.53 | -0.81 | -0.52 | -0.54 | 0.01 | -0.58 |
| R&D Expense | 217.87K | 92.44K | 111.60K | 321.44K | 604.11K | 407.57K | 913.97K | 2.48M | 2.45M | 1.81M | 2.26M | 3.18M | 2.52M | 1.84M | 2.26M | 721.48K | 763.90K | 2.41M | 938.04K | 631.11K | 985.88K | 1.28M | 1.44M | 1.63M | 707.93K | 567.23K | 1.33M | 438.28K | 1.39M | 1.09M | 1.68M | 2.05M | 2.18M | 2.53M | 2.59M | 2.73M | 2.12M |
Profit & Loss (Annual)
Figures in USD.
| Metric | Dec 2014 | Dec 2015 | Dec 2016 | Dec 2017 | Dec 2018 | Dec 2019 | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | - | 0 | 669.26K | 407.52K | 1.65M | 2.69M | 12.06K | 0 | - | 0 | 16.02M | 0 |
| Operating Income | - | - | - | - | -10.84M | - | -8.21M | -14.24M | -12.31M | -12.59M | 4.51M | -12.83M |
| Net Income | -1.77M | -16.62M | -13.34M | -13.22M | -10.81M | -7.10M | -8.09M | -13.77M | -13.58M | -12.51M | 3.59M | -10.84M |
| Diluted EPS | - | - | - | - | - | - | -1.77 | -57.12 | -18.55 | -24.25 | 0.87 | -2.64 |
| R&D Expense | 531.12K | 2.72M | 8.42M | 10.33M | 8.06M | 5.39M | 3.57M | 5.35M | 3.45M | 4.03M | 7.84M | 10.78M |
Balance Sheet (Annual)
Figures in USD.
| Metric | Dec 2013 | Dec 2014 | Dec 2015 | Dec 2016 | Dec 2017 | Dec 2018 | Dec 2019 | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Total Assets | - | 1.41M | 9.51M | 9.73M | 14.31M | 14.28M | 10.11M | 15.16M | 20.13M | 18.68M | 13.71M | 36.48M | 24.25M |
| Total Equity | -44.84M | -46.81M | 6.09M | -329.42K | -1.93M | 8.94M | 6.62M | 9.73M | 14.58M | 11.41M | 6.11M | 25.76M | 16.13M |
| Cash & Equivalents | 501.17K | 167.00K | 8.39M | 3.64M | 7.81M | 8.00M | 3.78M | 1.19M | 7.85M | 5.96M | 2.45M | 3.79M | 8.70M |
| Long Term Debt | - | - | - | - | - | - | 0 | 278.19K | - | - | - | - | - |
| Total Liabilities | - | - | 3.42M | 10.06M | 16.23M | 5.34M | 3.49M | 8.16M | 5.55M | 7.27M | 7.60M | 10.72M | 8.13M |
| Current Liabilities | - | 5.02M | 3.42M | 7.31M | 14.83M | 3.86M | 1.41M | 1.77M | 1.61M | 3.27M | 1.63M | 6.01M | 3.63M |
Cash Flows (Annual)
Figures in USD.
| Metric | Dec 2016 | Dec 2017 | Dec 2018 | Dec 2019 | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|---|---|---|---|---|
| Operating Cash Flow | -8.41M | -6.47M | -10.84M | -8.15M | -7.32M | -10.68M | -10.43M | -9.56M | 8.56M | -9.96M |
| Investing Cash Flow | 174.75K | -37.00K | -270.00K | 0 | -244.44K | -157.02K | 6.38K | 0 | -22.66M | 14.43M |
| Financing Cash Flow | 3.50M | 10.67M | 11.30M | 3.92M | 5.00M | 17.58M | 8.62M | 5.97M | 15.50M | 265.65K |
| Capital Expenditure | -0 | -37.00K | -20.00K | -0 | -20.08K | -63.87K | -0 | -0 | -6.26K | -110.79K |
| Free Cash Flow | -8.41M | -6.51M | -10.86M | -8.15M | -7.34M | -10.74M | -10.43M | -9.56M | 8.55M | -10.07M |
Ratios (Annual)
Figures in %.
| Metric | Dec 2014 | Dec 2015 | Dec 2016 | Dec 2017 | Dec 2018 | Dec 2019 | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Gross Margin % | - | - | - | - | - | - | - | - | - | - | - | - |
| Operating Margin % | - | - | - | - | -656.3% | - | -68,104.8% | - | - | - | 28.2% | - |
| Net Margin % | - | - | -1,993.8% | -3,243.5% | -654.2% | -264.2% | -67,102.9% | - | - | - | 22.4% | - |
| ROE % | 3.8% | -273.0% | 4,050.6% | 686.0% | -121.0% | -107.2% | -83.2% | -94.5% | -119.1% | -204.8% | 14.0% | -67.2% |
| ROCE % | - | - | - | - | -104.1% | - | -61.4% | -76.9% | -79.9% | -104.2% | 14.8% | -62.2% |
Shareholding Pattern
Analyst View
Analyst aggregate. Targets and ratings update periodically; not investment advice.
Latest News
Recent headlines for KPRX
Price to sales forward of Kiora Pharmaceuticals, Inc. – NASDAQ:KPRX - TradingView
<a href="https://news.google.com/rss/articles/CBMingFBVV95cUxPNm16OGFQcXhibHFZd0Y1MmgtMTFvYjhjUktGY0lQaHpVZnVOWmJ0MnRWMHJyaEJVMkpmX3hoaXNxRmxBakpxVG15cVVESHRlSlR4VDBUbW5hakgzSndnWk1LdFhGVmctNlk1S0k3QjFtOUlmbjFiMEhlNllhT1ctaXVRYWhGZ1RQdmtiRk…
Why Did KPRX Stock Surge 17% Pre-Market Today? - Stocktwits
<a href="https://news.google.com/rss/articles/CBMiqAFBVV95cUxOVHVwbkhLODJFTkljUXJfdlRqSDQ5NlRUVWVLbjhzNGpIdmkzdWdNR2hhU2NubHpXMHZrU1hGMlBMZFdkZlk2djhEWFViN2dwZEVCejl4M2w4ZHNvWjFrSG8yV3hYa1NOMmg2dlVfaE43eldXTVpDOW5QSTNBYnh5MVFDUHA4Z1V4MlRqdm…
Two biotech investors back Kiora with $5M now, $19M more later - Stock Titan
<a href="https://news.google.com/rss/articles/CBMiuAFBVV95cUxONVdodGVNTEVmbl80bWhWMklVU3VnQnlkX1ZmdGFvMV81RzZ5NXpnVUVWRjc1YTFpNVFlVGM4bGJpNWV3TnlOTjBpckxXUlFoT3hSSTN4SVk3M3laMU1vT1cxbVlsd3RpTE4yVkhiUVRjUXYxX3FvSjVSNWZNQ0RXX2Zobm14MnVKSmpaaG…
KPRX|Kiora Pharmaceuticals Inc|Price:2.560|Chg%:+0.030 - TradingKey
<a href="https://news.google.com/rss/articles/CBMibkFVX3lxTE15Q0Rqa21GQ3hUT3JKZ29uLWIwWHJjcXhldUd5SDZtdDJnQmhLUUl6MTNiVlFhWEhuN3ZkUlFIZFlBRURLWWRPb1ZReHI5eE11eGxqdmlYZVRMNGNsTF93VF9HUXlkRjJndVVHeVpR?oc=5" target="_blank">KPRX|Kiora Pharmace…
KPRX Forecast — Price Target — Prediction for 2027 - TradingView
<a href="https://news.google.com/rss/articles/CBMiekFVX3lxTE9tNHdvNkthdl8xQ0tKSnhac1kwbDNITHdGZE5XTnNPRmZRd1hxeWQxYUdmaEVndi01RnZjdXRBNy12UmdJMDhtNldKMjI1dDQ0dWdvMVZ0UE9uazByVnVvaXpteGtmQS1DalVqTVNPUV9tYzlHa25MVDdn?oc=5" target="_blank">KPR…
Kiora Pharmaceuticals’ Stock Analysis amidst Financial Challenges - StocksToTrade
<a href="https://news.google.com/rss/articles/CBMihAFBVV95cUxOdjBMNTRHbEZpcG9CbXZHSWtWbjNfZ25tNUZ5T2lCTVI4YTgyTnZJUFdKNmkzX3d2UVFDb3ZZVVBrQUtHc3pVVkRMN0daOUI3emtMQk9tVDl4UUtJWW9iUEJvQWpNdVo1YUYxMzVRSmpQNWZ1Z1ZBRlV2dDI3Z3FGMHgtZzM?oc=5" targ…
KPRX — Frequently Asked Questions
What is the current share price of KPRX?
As of 2026-08-05 17:25 PDT, KPRX trades at $2.54 on NASDAQ/NYSE. Its 52-week range is $1.80 to $2.93.
What is the P/E ratio of KPRX?
KPRX trades at a trailing price-to-earnings (P/E) ratio of -0.96.
What is the return on equity (ROE) of KPRX?
KPRX has a return on equity (ROE) of -67.19%. Its return on capital employed (ROCE) is -62.22%.
Is KPRX a good stock to buy?
This page provides a data-driven analysis of KPRX, including valuation ratios, profitability, growth trends, auto-generated pros and cons, peer comparison and AI exposure. Review these fundamentals alongside your own research and risk tolerance. This is informational content, not investment advice.